Literature DB >> 23696960

Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma.

Soley Bayraktar1, Caio M Rocha-Lima.   

Abstract

Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related death in both men and women in the United States. Platinum-based doublet chemotherapy has been a standard for patients with advanced stage disease. Improvements in overall survival and quality of life have been modest. Improved knowledge of the aberrant molecular signaling pathways found in NSCLC has led to the development of biomarkers with associated targeted therapeutics, thus changing the treatment paradigm for many NSCLC patients. In this review, we present a summary of many of the currently investigated biologic targets in NSCLC, discuss their current clinical trial status, and also discuss the potential for development of other targeted agents.

Entities:  

Keywords:  Anaplastic lymphoma kinase; BRAF; Epidermal growth factor receptor; Molecular targeted therapy; Non-small cell lung cancer; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Year:  2013        PMID： 23696960      PMCID： PMC3659261          DOI： 10.5306/wjco.v4.i2.29

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN： 2218-4333


  92 in total

1.  Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Authors:  Banibrata Sen; Shaohua Peng; Ximing Tang; Heidi S Erickson; Hector Galindo; Tuhina Mazumdar; David J Stewart; Ignacio Wistuba; Faye M Johnson
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

2.  Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

Authors:  Yasushi Yatabe; Keitaro Matsuo; Tetsuya Mitsudomi
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

3.  Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.

Authors:  Pasi A Jänne; Xiaofei Wang; Mark A Socinski; Jeffrey Crawford; Thomas E Stinchcombe; Lin Gu; Marzia Capelletti; Martin J Edelman; Miguel A Villalona-Calero; Robert Kratzke; Everett E Vokes; Vincent A Miller
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

4.  Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.

Authors:  Floriana Morgillo; Woo-Young Kim; Edward S Kim; Fortunato Ciardiello; Waun Ki Hong; Ho-Young Lee
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

Review 5.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

6.  Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.

Authors:  Daphne W Bell; Brian W Brannigan; Keitaro Matsuo; Dianne M Finkelstein; Raffaella Sordella; Jeff Settleman; Tetsuya Mitsudomi; Daniel A Haber
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

7.  Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

Authors:  R Rosell; G Robinet; A Szczesna; R Ramlau; M Constenla; B C Mennecier; W Pfeifer; K J O'Byrne; T Welte; R Kolb; R Pirker; A Chemaissani; M Perol; M R Ranson; P A Ellis; K Pilz; M Reck
Journal:  Ann Oncol       Date:  2007-10-17       Impact factor: 32.976

8.  Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Authors:  Nathan T Ihle; Robert Lemos; Peter Wipf; Adly Yacoub; Clint Mitchell; Doris Siwak; Gordon B Mills; Paul Dent; D Lynn Kirkpatrick; Garth Powis
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

9.  Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Bonne Biesma; David Heigener; Joachim von Pawel; Timothy Eisen; Jaafar Bennouna; Li Zhang; Meilin Liao; Yan Sun; Steven Gans; Kostas Syrigos; Etienne Le Marie; Maya Gottfried; Johan Vansteenkiste; Vincente Alberola; Uwe Phillip Strauss; Elaine Montegriffo; Teng Jin Ong; Armando Santoro
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962
View more
  6 in total

1.  Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer.

Authors:  Masayuki Aboshi; Masayuki Kaneko; Mamoru Narukawa
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-22       Impact factor: 4.553

2.  Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.

Authors:  Kian Ngiap Chua; Li Ren Kong; Wen Jing Sim; Hsien Chun Ng; Weijie Richard Ong; Jean Paul Thiery; Hung Huynh; Boon Cher Goh
Journal:  Oncotarget       Date:  2015-10-06

3.  Decreased IFIT2 Expression In Human Non-Small-Cell Lung Cancer Tissues Is Associated With Cancer Progression And Poor Survival Of The Patients.

Authors:  Wenya Su; Wenlu Xiao; Lujun Chen; Qi Zhou; Xiao Zheng; Jingfang Ju; Jingting Jiang; Zhigang Wang
Journal:  Onco Targets Ther       Date:  2019-10-03       Impact factor: 4.147

4.  Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.

Authors:  E C Martino; G Misso; P Pastina; S Costantini; F Vanni; C Gandolfo; C Botta; F Capone; A Lombardi; L Pirtoli; P Tassone; C Ulivieri; P Tagliaferri; M G Cusi; M Caraglia; P Correale
Journal:  Cell Death Discov       Date:  2016-10-03

Review 5.  A case report of tongue metastasis from lung squamous cell carcinoma and literature review.

Authors:  Xiaolong Cheng; Zhenli Hu; Yi-Ping Han; Chong Bai
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

6.  Adaptive metabolic rewiring to chronic SFK inhibition.

Authors:  Edgar Pinedo-Carpio; David Davidson; Veronica L Martinez Marignac; Justin Panasci; Raquel Aloyz
Journal:  Oncotarget       Date:  2016-03-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.